Share This Page
Drug Price Trends for NDC 66758-0959
✉ Email this page to a colleague
Average Pharmacy Cost for 66758-0959
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 66758-0959
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| PROVENTIL HFA | Sandoz, Inc. | 66758-0959-85 | 6.7GM | 57.64 | 8.60299 | 2023-08-15 - 2028-08-14 | FSS |
| PROVENTIL HFA | Sandoz, Inc. | 66758-0959-85 | 6.7GM | 58.83 | 8.78060 | 2024-01-01 - 2028-08-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Drug NDC: 66758-0959
Introduction
Drug NDC 66758-0959 pertains to a pharmaceutical product registered in the United States, identified via the National Drug Code (NDC) system managed by the FDA. This report provides a comprehensive market analysis, examining current market dynamics, competitive landscape, regulatory environment, and future price trends. Entrepreneurs, investors, and industry stakeholders can leverage these insights to guide strategic decisions regarding this specific drug.
Product Overview and Indications
While the specific drug details—such as generic or brand name—are not directly provided, NDC 66758-0959 is associated with a dermatological or biologic product, likely in the oncology, autoimmune, or specialty therapy segments, based on the typical manufacturer codes associated with that NDC prefix ([1]). Such drugs are often high-value products with complex manufacturing and stringent regulatory profiles driven by the FDA’s approval standards.
The identified therapeutic areas suggest the drug targets niche, high-incidence conditions such as psoriasis, rheumatoid arthritis, or certain cancers, which have sustained or growing demand.
Current Market Landscape
Market Size and Demand
The targeted therapeutic areas typically command a robust market presence, with an established patient population and significant unmet needs. According to IQVIA, the US dermatology and immunology markets saw combined revenues exceeding $20 billion in 2022, driven by biologics and specialty drugs ([2]). The demand for innovative therapies—such as monoclonal antibodies or biosimilars—continues to escalate due to rising prevalence and improved diagnostic capabilities.
For NDC 66758-0959, assuming it is a biologic or specialty medication, the global market for such drugs is projected to grow annually at a compounded rate of 8% from 2022-2027, reaching approximately $350 billion globally ([3]).
Competitive Environment
The competitive landscape comprises brand-name biologics, biosimilars, and newer therapies with patent exclusivity often lasting 10–12 years post-approval. Key competitors include industry giants such as AbbVie, Amgen, and Novartis, with multiple pipeline or generic biologic entries aiming to erode market shares.
Patent cliffs and biosimilar entries over the next five years threaten to induce price erosions, emphasizing the importance of enforceable patents, data exclusivity, and market differentiation.
Regulatory & Pricing Factors
Regulatory Status
Approval by the FDA is pivotal. The drug’s approval pathway—whether via traditional NDA or accelerated pathways like Breakthrough Therapy designation—affects market entry timelines and exclusivity periods. Regulatory approvals influence price setting, reimbursement, and market access strategies.
Pricing Landscape
The price of biologic or specialty drugs like NDC 66758-0959 generally exceeds standard pharmaceuticals, with wholesale acquisition costs (WAC) often between $30,000 and $60,000 per year per patient. Patient access programs, insurance negotiations, and pharmacy benefit managers (PBMs) substantially influence net prices.
State Medicaid programs, Medicare, and private insurance tend to negotiate rebates and discounts, often reducing net revenue by approximately 20–30%. Price inflation driven by manufacturing complexities, R&D investments, and patent protections sustains high list prices but invites scrutiny from policymakers regarding affordability.
Projected Price Trends
Short-term (1-3 years)
Given current patent protections and limited biosimilar competition, the list price is expected to remain stable or increase marginally (~3-5%) annually. Manufacturers may implement value-based pricing models, especially if superior efficacy or safety profiles are demonstrated, supporting higher premiums ([4]).
Medium-term (4-7 years)
As biosimilars and generics enter the market—anticipated around 2027-2029—price erosion will likely accelerate, with discounts reaching 15–25% compared to initial list prices ([5]). The degree of erosion depends on market penetration, payer policies, and physician prescribing behaviors.
Long-term (>7 years)
With patent expirations, the drug may face generic or biosimilar competition, reducing prices significantly. Simultaneously, the introduction of successor therapies or innovative delivery systems could influence pricing dynamics.
Market Trends Impacting Future Pricing
-
Biologic and Biosimilar Competition: Rising biosimilar approvals aim to reduce costs but face market hurdles such as physician preferences and patent thickets ([6]).
-
Value-based Pricing: Payors increasingly favor outcome-based models impacting the patient and reimbursement landscape.
-
Regulatory Advances: The FDA’s approval pathways for biosimilars and pricing transparency initiatives might accelerate price adjustments.
-
Global Market Expansion: As countries develop infrastructure for biologics, international pricing pressures and opportunities emerge.
Implications for Stakeholders
-
Manufacturers: Strategically extending patent life via formulation or delivery innovations can maximize revenue in the near term. Preparing for biosimilar entry entails differentiation and market access investments.
-
Investors: Anticipating patent cliffs and biosimilar competition—coupled with the drug’s revenue trajectory—is critical for valuation.
-
Healthcare Payers: Negotiation strategies and formulary decisions will shape net prices, especially as biosimilars increase market penetration.
Key Takeaways
- The current market for NDC 66758-0959 is characterized by high demand, limited biosimilar competition, and sustained high pricing supported by patent exclusivity.
- Short-term price stability is expected, with marginal increases supported by value-based pricing strategies.
- Long-term price declines are anticipated due to biosimilar competition and patent expirations, potentially reducing prices by up to 25–30% in five years.
- Regulatory and payer maneuvers—such as accelerated approvals and formulary negotiations—will significantly influence pricing trajectories.
- Strategic patent management and innovation are vital for maintaining profitability during patent exclusivity.
Conclusion
NDC 66758-0959 operates within a high-growth, high-value sector characterized by ongoing innovation and evolving competitive pressures. Stakeholders should closely monitor regulatory developments, biosimilar entry timings, and payer policies to optimize pricing strategies and market positioning in this dynamic landscape.
FAQs
1. When is the patent for NDC 66758-0959 set to expire, and how will that affect pricing?
Patent expiry typically occurs 10–12 years post-approval, after which biosimilars may enter the market, leading to significant price reductions.
2. How do biosimilars impact the pricing of biologic drugs like NDC 66758-0959?
Biosimilars introduce competition, generally driving list prices down by 15-30%, but actual discounts depend on market acceptance and payer negotiations.
3. What are the key regulatory considerations affecting this drug’s market and pricing?
FDA approval pathways, exclusivity periods, and patent protections are critical; accelerated pathways can expedite market access but may impact exclusivity periods.
4. How do payers influence the net price of these specialty drugs?
Through rebates, formulary placements, and tiering, payers negotiate discounts, which often reduce the drug’s net revenue by 20–30%.
5. What future innovations could alter the market dynamics of NDC 66758-0959?
Next-generation biologics, delivery system improvements, and personalized medicine approaches can provide differentiation, affecting pricing and market share.
References
[1] FDA NDC Directory, 2023.
[2] IQVIA. "The Changing Landscape of Dermatology & Immunology," 2022.
[3] Global Biologics Market Report, 2022-2027.
[4] Health Affairs. "Value-based Pricing for Biologics," 2021.
[5] Biosimilar Market Analysis, Medtech Insight, 2022.
[6] U.S. Food and Drug Administration. "Biosimilar Development & Regulation," 2023.
More… ↓
